Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT01536639

BIASP-1929

Details and patient eligibility

About

This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin regimen in routine clinical practice in the Slovak Republic.

Enrollment: 454 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Subjects with type 2 diabetes

Trial design

454 participants in 1 patient group

BIAsp 30 users

Treatment:

Drug: biphasic insulin aspart 30